Match!
Magdalena Wladysiuk
9Publications
6H-index
181Citations
Publications 9
Newest
Published on Dec 28, 2017in PLOS ONE2.78
Evelien Moorkens3
Estimated H-index: 3
(Katholieke Universiteit Leuven),
Arnold G. Vulto38
Estimated H-index: 38
(Erasmus University Medical Center)
+ 31 AuthorsLjiljana Sović-Brkičić2
Estimated H-index: 2
markdownabstract__Background__ Across European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe. __Objectives__ The aim of this article is to provide an overview of different initiatives and policies that may influence the uptake of biosimilars in different European countries. Recommendations will be formulated on how to create sustainable uptake. __Methods__ An overview of policies on biosimilars was o...
Published on Jul 22, 2016in Frontiers in Pharmacology3.85
Winnie de Bruijn1
Estimated H-index: 1
(UU: Utrecht University),
Cristina Ibáñez2
Estimated H-index: 2
+ 37 AuthorsJ. Eriksen16
Estimated H-index: 16
(Karolinska University Hospital)
Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines ...
Published on Jun 10, 2014in Frontiers in Pharmacology3.85
Brian Godman36
Estimated H-index: 36
(Strathclyde Institute of Pharmacy and Biomedical Sciences),
Rickard E. Malmström21
Estimated H-index: 21
(Karolinska University Hospital)
+ 33 AuthorsAnna Bucsics15
Estimated H-index: 15
(University of Vienna)
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/ or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal ...
Published on Dec 1, 2013in BMC Medicine8.29
Brian Godman36
Estimated H-index: 36
(FIOCRUZ: Oswaldo Cruz Foundation),
Alexander Finlayson14
Estimated H-index: 14
(Weston Education Centre)
+ 42 AuthorsMarion Bennie21
Estimated H-index: 21
(University of Strathclyde)
Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and ...
Magdalena Wladysiuk6
Estimated H-index: 6
,
Anna Tabor1
Estimated H-index: 1
,
Brian Godman36
Estimated H-index: 36
‘HTA for Crisis’ – 7th Evidence-Based Health Care Symposium organized by the Central and Eastern European Society for Technology Assessment in HealthcareKrakow, Poland, 8–9 October 2012The Central and Eastern European Society of Technology Assessment in Health Care was founded in Krakow, Poland in 2003. On October 8th and 9th, the 7th symposium took place titled ‘HTA for Crisis’. This meeting was attended by over 250 decision makers, evidence-based specialists, healthcare managers, commercial co...
Published on Jan 1, 2013in Frontiers in Pharmacology3.85
Rickard E. Malmström21
Estimated H-index: 21
(Karolinska University Hospital),
Brian Godman36
Estimated H-index: 36
(KI: Karolinska Institutet)
+ 44 AuthorsAlessandra Ferrario11
Estimated H-index: 11
(LSE: London School of Economics and Political Science)
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/ or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular AF, exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination. Published studies have s...
Aleksander Araszkiewicz11
Estimated H-index: 11
,
Katarzyna Szabert2
Estimated H-index: 2
+ 3 AuthorsAlan Haycox35
Estimated H-index: 35
(University of Liverpool)
Pressures to contain pharmaceutical expenditure have led to increased prescribing and dispensing of generic drugs in addition to low prices for generics. Atypical antipsychotics are prescribed for schizophrenia leading to resource pressures with their higher acquisition costs than typical antipsychotics. Drug costs can be reduced once multiple sources are available. However, this must be balanced against possible efficacy, safety and compliance concerns given the high cost of relapses for patien...
Published on Jan 1, 2008
A Aleksander , Katarzyna Szabert2
Estimated H-index: 2
+ 3 AuthorsAlan Haycox35
Estimated H-index: 35
Pressures to contain pharmaceutical expenditure have led to increased prescribing and dispensing of generic drugs in addition to low prices for generics. Atypical antipsychotics are prescribed for schizophrenia leading to resource pressures with their higher acquisition costs than typical antipsychotics. Drug costs can be reduced once multiple sources are available. However, this must be balanced against possible efficacy, safety and compliance concerns given the high cost of relapses for patien...
1